AN
ANRO.US Alto Neuroscience, Inc.
- Market cap
- USD 1.18B
- P/E
- -
- P/B
- 4.14x
- ROE
- -32.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Sep 2026.
Is ANRO.US undervalued?
Graham numberThe Graham number of Alto Neuroscience, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alto Neuroscience, Inc. fundamental analysis
No fundamental analysis for Alto Neuroscience, Inc. yet.
Alto Neuroscience, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a no…
Full company profileAlto Neuroscience, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 4 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alto Neuroscience, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 210K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 65.0K | -342K | -373K | -502K | -661K | - |
| Operating Income | -12.1M | -29.2M | -37.8M | -68.6M | -66.4M | 32.2M |
| EBITDA | -9.04M | -27.4M | -34.6M | -62.3M | -60.1M | -91.4M |
| Net Income | -9.19M | -27.7M | -36.3M | -61.4M | -63.2M | -95.2M |
| EPS | -0.36 | -1.08 | -1.35 | -2.50 | -2.19 | -2.05 |
| Balance Sheet | ||||||
| Total Assets | 28.8M | 50.9M | 86.6M | 178M | 185M | 327M |
| Total Liabilities | 41.3M | 89.3M | 158M | 26.1M | 33.5M | 30.0M |
| Shareholders' Equity | -12.5M | -38.4M | -71.7M | 151M | 151M | 297M |
| Cash & Short-term Investments | 25.7M | 48.3M | 82.5M | 168M | 176M | 319M |
| Total Debt | 38.2M | 82.1M | 9.99M | 16.9M | 4.41M | 15.5M |
| Cash Flow | ||||||
| Operating Cash Flow | -9.26M | -20.4M | -33.4M | -47.4M | -51.8M | -79.1M |
| Capital Expenditure | 680K | 732K | 470K | 2.08M | 24.0K | 556K |
| Free Cash Flow | -9.94M | -21.1M | -33.9M | -49.5M | -51.8M | -79.7M |
| Ratios | ||||||
| ROE | - | - | - | -40.6% | -41.8% | -32.1% |
| ROA | -31.9% | -54.5% | -41.9% | -34.6% | -34.2% | -29.2% |
| Net Profit Margin | -4,374.8% | - | - | - | - | - |
| Debt to Equity | - | - | - | 0.11x | 0.03x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Alto Neuroscience, Inc. dividends
Alto Neuroscience, Inc. has not paid dividends in the last 5 fiscal years.
Who owns Alto Neuroscience, Inc.
- Insiders 4.12%
- Institutions 89.56%
- Public & others 6.32%
- Shares outstanding 40.1M
- Free float 30.2M
Top funds holding ANRO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.21M | 3.07% | +19.11% | Sep 2026 |
| iShares Russell 2000 ETF | 814K | 2.07% | 0.00% | Oct 2026 |
| Franklin Biotechnology Discv A(acc)USD | 646K | 1.65% | 0.00% | Sep 2026 |
| T. Rowe Price Health Sciences | 501K | 1.28% | 0.00% | Sep 2026 |
| Franklin Biotechnology Discovery A | 348K | 0.89% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 299K | 0.76% | -0.38% | Oct 2026 |
| Fidelity Small Cap Index | 287K | 0.73% | 0.00% | Aug 2026 |
| iShares Biotechnology ETF | 274K | 0.70% | -1.94% | Oct 2026 |
| T. Rowe Price New Horizons | 267K | 0.68% | +7.01% | Sep 2026 |
| Heptagon Driehaus US Micro Cap Eq C$ Acc | 264K | 0.67% | 0.00% | Sep 2026 |
| Biotech Growth Ord | 258K | 0.66% | 0.00% | Jul 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 224K | 0.57% | +2.88% | Oct 2026 |
| Invesco Dorsey Wright SmallCap Momt ETF | 219K | 0.56% | -0.54% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 209K | 0.53% | +0.23% | Oct 2026 |
| Vanguard Russell 2000 ETF | 186K | 0.47% | +23.39% | Sep 2026 |
| Fidelity Extended Market Index | 179K | 0.46% | +21.95% | Sep 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 142K | 0.36% | 0.00% | Sep 2026 |
| Invesco Dorsey Wright Healthcare MomtETF | 121K | 0.31% | 0.00% | Oct 2026 |
| Fidelity Advisor Biotechnology I | 119K | 0.30% | 0.00% | Sep 2026 |
| Driehaus Micro Cap Growth USD | 107K | 0.27% | +1.16% | Sep 2026 |
Top institutions holding ANRO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Alpha Wave Global LP | 3.71M | 9.45% | 0.00% | Jun 2026 |
| COMMODORE CAPITAL LP | 2.72M | 6.94% | 0.00% | Jun 2026 |
| BlackRock Inc | 2.12M | 5.40% | +218.38% | Jun 2026 |
| Perceptive Advisors LLC | 1.61M | 4.10% | -19.90% | Jun 2026 |
| Adage Capital Partners Gp LLC | 1.60M | 4.08% | +315.58% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.39M | 3.54% | +15.12% | Jun 2026 |
| Spruce Street Capital LP | 1.35M | 3.45% | +2.10% | Jun 2026 |
| Vivo Capital, LLC | 1.21M | 3.08% | +16.74% | Jun 2026 |
| Franklin Templeton Inc | 1.01M | 2.58% | -8.04% | Jun 2026 |
| Armistice Capital, LLC | 864K | 2.20% | -5.26% | Jun 2026 |
| Affinity Asset Advisors, LLC | 850K | 2.17% | +70.00% | Jun 2026 |
| Vestal Point Capital LP | 785K | 2.00% | -61.97% | Jun 2026 |
| State Street Corp | 686K | 1.75% | +243.83% | Jun 2026 |
| Geode Capital Management, LLC | 678K | 1.73% | +131.55% | Jun 2026 |
| 72 Investment Holdings, LLC | 668K | 1.70% | 0.00% | Jun 2026 |
| Northern Trust Corp | 633K | 1.61% | +33.65% | Jun 2026 |
| Millennium Management LLC | 558K | 1.42% | -32.08% | Jun 2026 |
| Point72 Asset Management, L.P. | 503K | 1.28% | -0.03% | Jun 2026 |
| VR Adviser, LLC | 500K | 1.27% | 0.00% | Jun 2026 |
| Integral Health Asset Management, LLC | 500K | 1.27% | 0.00% | Jun 2026 |
Alto Neuroscience, Inc. company profile
- Company name
- Alto Neuroscience, Inc.
- Ticker
- ANRO.US
- Exchange
- USA Stocks
- Listed since
- Feb 2, 2024
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 68
- Fiscal year end
- September
- Address
- 650 Castro Street, Mountain View, CA, United States, 94041
- Phone
- 650 200 0412
- Website
- altoneuroscience.com
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Alto Neuroscience, Inc. management
7- Dr. Amit Etkin M.D., Ph.D.Founder, CEO & Chairman of the Board · born 1977
- Mr. Nicholas C. SmithCFO & President · born 1989
- Mr. Michael C. Hanley M.B.A.Chief Operating Officer · born 1974
- Mr. Dan Segal B.Sc. (Hons), BCom, CA, MScCo-Founder & Strategic Advisor · born 1962
- Ms. Erin R. McQuade J.D.General Counsel, Chief Administrative Officer & Corporate Secretary · born 1975
- Mr. Adam Savitz M.D., Ph.D.Chief Medical Officer · born 1966
- Ms. Jessica PowellChief Development Officer · born 1975